List of Excipients in Branded Drug IMVEXXY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mayne Pharma LLC	IMVEXXY	estradiol	50261-104	ALCOHOL
Mayne Pharma LLC	IMVEXXY	estradiol	50261-104	AMMONIA
Mayne Pharma LLC	IMVEXXY	estradiol	50261-104	ETHYL ACETATE
Mayne Pharma LLC	IMVEXXY	estradiol	50261-104	FD&C RED NO. 40
Mayne Pharma LLC	IMVEXXY	estradiol	50261-104	GELATIN

IMVEXXY Excipient Strategy and Commercial Opportunities in Vaginal Estradiol

Last updated: August 2, 2026

IMVEXXY is a differentiated vaginal estradiol product built around an ultra-low-dose, softgel insert rather than a cream, tablet, or ring. Its commercial value comes from dose flexibility, low-volume administration, product handling, and patient preference. The main excipient opportunity is not simple cost substitution. It is the development of a softgel platform that improves capsule integrity, drug uniformity, vaginal retention, manufacturing yield, and regulatory defensibility.

IMVEXXY contains estradiol at 4 mcg and 10 mcg strengths and is approved for moderate-to-severe dyspareunia associated with vulvar and vaginal atrophy due to menopause.[1] The product is marketed in the United States by Mayne Pharma following its acquisition of TherapeuticsMD's women's health assets.[2]

What is IMVEXXY and how does its formulation differ from competing vaginal estrogen products?

IMVEXXY is a vaginal insert containing estradiol in a small softgel capsule. The commercial dosage strengths are 4 mcg and 10 mcg.

Product	Active ingredient	Dosage form	Typical administration	Formulation position
IMVEXXY	Estradiol	Softgel vaginal insert	Daily for two weeks, then twice weekly	Ultra-low-dose insert
Vagifem/Yuvafem	Estradiol	Vaginal tablet or insert	Daily loading, then twice weekly	Solid dosage form
Estradiol vaginal cream	Estradiol	Cream	Variable, patient-measured application	Semisolid, higher handling burden
Estring	Estradiol	Vaginal ring	Replaced approximately every 90 days	Long-duration device
Premarin vaginal cream	Conjugated estrogens	Cream	Variable schedule	Semisolid estrogen formulation

IMVEXXY's dosage form addresses several limitations associated with creams. It delivers a fixed dose, avoids an applicator for administration, and reduces the need for patients to measure or dispense a semisolid product. The softgel format also creates a distinct product experience compared with generic estradiol tablets.

What excipients are used in IMVEXXY?

The commercial capsule uses a lipid-based or softgel-compatible fill system and a gelatin shell. The FDA prescribing information identifies inactive components including hard fat, gelatin, glycerin, titanium dioxide, and color additives.[1]

The excipient functions are divided between the fill and the shell:

Excipient class	Primary function	Commercial relevance
Hard fat or lipid vehicle	Solubilizes or disperses estradiol and creates the capsule fill	Controls dose uniformity, release, and capsule processing
Gelatin	Forms the softgel shell	Controls mechanical strength, sealing, dissolution, and stability
Glycerin	Plasticizes gelatin	Affects shell flexibility and brittleness
Titanium dioxide and colorants	Opacity and product identification	Supports appearance and brand recognition
Antioxidant or stabilizer system, where used	Limits oxidative degradation	Can affect shelf life and impurity profile

The key formulation challenge is the extremely low estradiol load. At 4 mcg, the active ingredient represents a very small fraction of the total fill. Manufacturing performance therefore depends on uniform dispersion, low adsorption to processing equipment, controlled fill weight, and validated content-uniformity testing.

What excipient strategy supports an IMVEXXY generic or follow-on product?

A competitive excipient strategy should prioritize four objectives: estradiol uniformity, softgel manufacturability, vaginal residence, and bioequivalence.

How can the fill vehicle improve drug uniformity?

Estradiol is poorly water-soluble. A lipid vehicle can maintain the active ingredient in solution or a controlled dispersed state. Candidate vehicles include medium-chain triglycerides, hard fats, oleic-acid derivatives, and other pharmaceutically accepted lipophilic carriers.

The commercial choice depends on:

• Estradiol solubility at the target concentration.
• Risk of crystallization during storage.
• Fill viscosity and pumpability.
• Compatibility with gelatin.
• Capsule leakage and seam integrity.
• Oxidative stability.
• Vaginal irritation potential.
• Cleaning and recovery losses during manufacturing.

For a 4 mcg product, a vehicle that produces a stable molecular solution may offer a stronger manufacturing position than a suspension. A suspension can create challenges with sedimentation, fill-to-fill variability, and sampling representativeness. A solution, however, requires sufficient solubility and must remain physically stable across the labeled temperature range.

Can a non-gelatin shell create a commercial opportunity?

Potentially. Hydroxypropyl starch, pullulan, and other non-gelatin shells could support vegetarian or religious-compliance positioning. The opportunity is limited by technical and regulatory requirements.

A non-gelatin shell would need to match or exceed:

• Water-vapor transmission performance.
• Mechanical strength during packaging and insertion.
• Seam integrity.
• Dissolution in vaginal fluid.
• Compatibility with the lipid fill.
• Long-term stability.
• Manufacturing speed and yield.

The shell is also a possible source of product differentiation. A thinner or faster-dissolving shell could improve patient experience, but any change that alters estradiol exposure, residence time, or local tolerability would create regulatory comparability work.

Can excipients reduce vaginal leakage?

Vaginal leakage is a product-design issue rather than an active-ingredient issue. A lower-viscosity fill may disperse rapidly but increase leakage. A higher-melting or more structured lipid fill may improve retention but slow drug release.

Commercially relevant approaches include:

1. Selecting a lipid vehicle that liquefies near vaginal temperature.
2. Controlling fill volume to minimize expelled material.
3. Modifying shell thickness and dissolution time.
4. Using a mucoadhesive excipient, subject to local tolerability and regulatory acceptability.
5. Designing the capsule to rupture or dissolve predictably after insertion.

Mucoadhesive polymers could create a differentiated product, but they also increase formulation risk. They may change local exposure, residue, patient perception, and vaginal microbiome interactions. A simple softgel with reproducible disintegration is likely to have a lower development burden than a strongly mucoadhesive system.

What formulation patents protect IMVEXXY?

IMVEXXY's protection is associated with estradiol vaginal insert formulations and related product claims rather than only the chemical identity of estradiol. Public Orange Book and patent records identify multiple U.S. patents associated with IMVEXXY, including patents in the US 9,937,191 and US 10,292,940 series.[3]

IP category	Relevance to IMVEXXY	Generic risk
Estradiol vaginal insert composition	Protects the active ingredient in a defined softgel or vaginal-insert formulation	High if claims cover broad vehicle and dosage ranges
Low-dose estradiol formulation	May cover 4 mcg and 10 mcg strengths or defined concentration ranges	Depends on claim construction and prosecution history
Capsule or delivery characteristics	Can cover shell, fill, dissolution, or release properties	Creates design-around opportunities
Method of treatment	May cover treatment of vulvar and vaginal atrophy or dyspareunia	Can support a Paragraph IV dispute
Manufacturing process	May cover filling, sealing, or preparation of the dosage form	Important for supplier and manufacturing barriers

Patent scope must be assessed claim by claim. A generic manufacturer may avoid a formulation claim by changing the lipid vehicle, shell material, capsule dimensions, concentration, or release profile. The strength of the estate depends on whether the patents claim the commercial product broadly or rely on narrow formulation limitations.

When does IMVEXXY lose exclusivity?

IMVEXXY received FDA approval in 2018. Its commercial exclusivity is governed by several separate protections:

• FDA regulatory exclusivity.
• Orange Book-listed patents.
• Method-of-use protections.
• Any pediatric exclusivity.
• Patent term adjustment or extension.
• Litigation-related automatic stays.

The principal commercial issue is patent expiry, not five-year new chemical entity exclusivity. Estradiol is an established active ingredient, so IMVEXXY did not receive new chemical entity exclusivity for the molecule itself.

Public patent databases associate key IMVEXXY formulation patents with expiration dates in the early 2030s, subject to patent-term adjustment, terminal disclaimers, pediatric exclusivity, and the specific patent claims listed in the current Orange Book.[3,4] A generic launch before the last blocking patent expiry would generally require a successful Paragraph IV challenge, a settlement permitting earlier entry, or a non-infringing product that avoids the listed claims.

What is the Orange Book status of IMVEXXY?

IMVEXXY is an FDA-approved prescription drug with Orange Book-listed patent information. The Orange Book identifies approved strengths, dosage form, therapeutic equivalence information, and patent listings submitted by the drug sponsor.[4]

The practical implications are:

• An ANDA applicant must address each listed patent.
• A Paragraph IV certification can trigger patent litigation.
• A valid Paragraph IV notice can create a 30-month stay of ANDA approval if the patent holder files suit within the statutory period.
• A generic may file a section viii statement for a method-of-use patent if its label omits the protected use.
• The presence of a patent listing does not establish that every claim is valid or infringed.

For IMVEXXY, formulation patents are more commercially important than broad estradiol composition patents because estradiol itself is long established. The relevant litigation question is whether the generic's capsule and fill system fall within the asserted insert claims.

Which companies are challenging IMVEXXY's patents?

Publicly reported generic activity should be tracked through FDA Paragraph IV notices, patent litigation dockets, and the Orange Book. The principal potential challengers are established generic manufacturers with softgel capabilities, including firms experienced in softgel manufacturing, vaginal products, or complex dosage forms.

The most credible challengers are those with:

• Existing estradiol manufacturing infrastructure.
• Softgel filling and sealing capacity.
• The ability to conduct comparative dissolution and pharmacokinetic studies.
• Experience with complex-product ANDAs.
• A commercial portfolio in women's health.

A conventional tablet manufacturer may face higher development risk because IMVEXXY's dosage form is itself a central part of the product's differentiation. A softgel manufacturer can more readily pursue a same-dosage-form strategy, while a non-softgel manufacturer may attempt a different dosage form but would face greater regulatory and substitutability issues.

What Paragraph IV risks exist for IMVEXXY?

Paragraph IV risk is material because the product's expected value rests on formulation and delivery claims that may be vulnerable to design-around arguments.

Generic launch scenarios

Scenario	Timing	Commercial effect
No accepted ANDA challenge	After final patent expiry	Delayed generic entry with strong erosion potential
Paragraph IV filing with litigation	Potentially before patent expiry	Approval may be delayed by litigation or the 30-month stay
Successful invalidity or non-infringement case	Before listed expiry	Earlier generic launch and rapid price erosion
Settlement with licensed entry	Agreed date before or at expiry	Predictable but potentially earlier erosion
Authorized generic or product acquisition	Sponsor-controlled timing	Can moderate independent generic penetration
Section viii carve-out	Depends on the patent claim	May allow approval with a narrowed label

A generic competitor could target the 10 mcg strength first because it may have greater market demand, then add the 4 mcg strength after resolving formulation and regulatory issues. The reverse strategy is also possible if the lower strength has simpler content-uniformity or commercial positioning.

How strong is the IMVEXXY patent estate?

The estate is moderately strong from a product-differentiation perspective but not unassailable.

Strengths

• The product uses a defined dosage form that differs from generic vaginal tablets and creams.
• Ultra-low-dose content creates technical barriers around uniformity and stability.
• Softgel manufacturing requires specialized equipment and process controls.
• Multiple formulation and method-of-use patents can increase litigation complexity.
• A generic must demonstrate pharmaceutical equivalence and bioequivalence in a locally acting vaginal product.

Weaknesses

• Estradiol is an old and widely used active ingredient.
• Alternative lipid vehicles are available.
• Softgel shell and fill changes may support design-around arguments.
• Local vaginal products may present complicated bioequivalence questions, but those same questions can weaken broad assumptions about formulation-based exclusivity.
• Patent claims limited to particular excipients, concentrations, or processing steps may be narrow.

The strongest commercial claims are likely those tied to the combination of ultra-low estradiol dose, softgel architecture, and defined release or composition parameters. Narrow claims covering a single excipient or manufacturing step are more vulnerable to substitution.

What excipient opportunities exist for IMVEXXY line extensions?

The most attractive opportunities are product extensions that retain the softgel platform while solving identifiable patient or channel problems.

Lower-cost generic-compatible softgel

A lower-cost formulation could use a simpler shell color system, a standardized lipid vehicle, and a manufacturing process optimized for high throughput. The primary value would be cost reduction rather than clinical differentiation.

Longer-acting vaginal insert

A higher-retention or slower-release insert could reduce administration frequency. This would require new clinical and local-tolerability evidence because changing residence time can change local estradiol exposure. It would likely require a new formulation patent family.

Preservative-free vaginal product

A single-use softgel already has a favorable preservative profile compared with multidose creams. A preservative-free positioning could support pharmacy, telehealth, and patient-preference channels.

Non-animal-derived capsule

A plant-derived shell could address patient preferences and institutional purchasing policies. The commercial opportunity depends on achieving equivalent mechanical and dissolution performance without increasing manufacturing cost.

Combination vaginal therapy

A softgel could potentially deliver estradiol with another locally acting ingredient, such as a moisturizer or microbiome-supporting component. This creates formulation and regulatory complexity. A combination product would require careful assessment of drug-drug compatibility, local safety, and whether the second component changes absorption or therapeutic effect.

Compounded or specialty-pharmacy alternatives

Compounded estradiol inserts may compete on price or dose customization but lack the same FDA-approved product status and standardized manufacturing controls. A branded manufacturer can defend its position through quality consistency, patient support, reimbursement access, and supply reliability.

How does IMVEXXY compare commercially with vaginal estradiol tablets and creams?

IMVEXXY's commercial differentiation is strongest where patients or prescribers value clean administration, fixed dosing, and a small insert. Its main disadvantages are likely product cost and the potential for generic substitution once formulation patents expire or are successfully challenged.

Commercial factor	IMVEXXY	Vaginal tablet	Vaginal cream
Dose precision	High	High	Moderate
Administration convenience	High	Moderate to high	Lower
Applicator dependence	Low	Often moderate	Often high
Manufacturing complexity	High	Moderate	Moderate
Generic substitution risk	Delayed by dosage-form patents	High for established tablet products	High
Excipient differentiation	High	Moderate	Moderate
Patient leakage concerns	Product-specific	Product-specific	Commonly reported concern
Price pressure	Higher branded positioning	Strong generic pressure	Strong generic pressure

IMVEXXY's commercial defense should focus on adherence, patient preference, fixed dosing, product quality, and reimbursement rather than on estradiol's clinical novelty.

What manufacturing and IP barriers affect commercial entry?

The principal manufacturing barrier is not the cost of estradiol. It is reliable production of a low-dose softgel at commercial scale.

Critical process controls include:

• Estradiol pre-dispersion or dissolution.
• Fill-weight precision.
• Homogeneity throughout the batch.
• Gelatin moisture control.
• Seam integrity.
• Capsule drying.
• Residual solvent and impurity control.
• Packaging protection from heat, oxygen, and moisture.
• Stability under long-term and accelerated conditions.

Specialized softgel capacity can limit the number of credible generic entrants. Contract manufacturing agreements, proprietary process parameters, equipment availability, and validated suppliers can create practical barriers even where patent protection is weaker.

Geographic protection is likely to be strongest in the United States because the product's commercial value and Orange Book framework are U.S.-centered. European and other markets may use different regulatory classifications, patent claims, reimbursement systems, and estrogen product standards. A global strategy should separately evaluate U.S., European, Canadian, Australian, and Asian patent families rather than assume that U.S. formulation claims transfer directly.

What licensing deals and commercial partnerships matter for IMVEXXY?

The key commercial transaction was Mayne Pharma's acquisition of TherapeuticsMD's women's health assets, including IMVEXXY, in 2022.[2] That transaction transferred commercial rights and related product infrastructure to Mayne Pharma.

Future licensing opportunities could involve:

• Regional rights outside the United States.
• Softgel manufacturing partnerships.
• Authorized generic supply.
• Co-development of a lower-cost formulation.
• Non-gelatin capsule technology.
• Long-acting vaginal delivery systems.
• Digital adherence and patient-support programs.

For an excipient supplier, the most valuable entry point is a platform agreement covering multiple vaginal products rather than a single excipient sale. The supplier should seek protection for composition, processing, and product-performance parameters. A formulation that can be adapted to estradiol, progesterone, or other vaginally delivered actives has greater licensing value.

What revenue exposure exists if IMVEXXY faces generic entry?

Generic entry would likely affect net price before it eliminates branded demand. The magnitude depends on the number of approved ANDAs, whether the generic is therapeutically substitutable, payer formulary rules, and whether an authorized generic is introduced.

Entry condition	Expected brand impact
One generic entrant	Moderate price and volume pressure
Several same-form generic entrants	Rapid discounting and share loss
Tablet or cream alternatives only	Lower direct substitution pressure
Softgel-equivalent generic	High direct erosion risk
Authorized generic launch	Potentially reduces third-party generic opportunity
Patent settlement with delayed entry	Preserves value through the settlement date

The product's strongest revenue defense is a differentiated patient experience that is visible to prescribers and patients. Excipient changes that improve leakage, insertion comfort, stability, or storage can support lifecycle management, but they must be supported by evidence and a clear reimbursement rationale.

What is the commercial outlook for IMVEXXY excipient innovation?

The most defensible opportunity is an improved softgel platform with measurable performance benefits:

1. Better estradiol content uniformity at 4 mcg.
2. Faster, more predictable shell dissolution.
3. Lower leakage after administration.
4. Improved heat and humidity stability.
5. Lower-cost, high-yield manufacturing.
6. A non-animal-derived shell with equivalent performance.
7. A new patent family covering the composition and manufacturing process.

A minor excipient substitution without a patient, manufacturing, or patent benefit is unlikely to create substantial commercial value. The strongest programs combine formulation savings with a new product claim, such as improved retention, reduced administration burden, or extended stability.

Key Takeaways

• IMVEXXY is a 4 mcg and 10 mcg estradiol vaginal softgel insert approved for menopausal vulvar and vaginal atrophy-related dyspareunia.
• Its excipient strategy depends on a lipid fill, gelatin-based softgel shell, plasticizer control, and ultra-low-dose content uniformity.
• The principal competitive barrier is the combination of formulation IP and specialized softgel manufacturing.
• Estradiol itself is old and widely available, so commercial protection depends on dosage form, formulation, method of use, and process claims.
• Orange Book-listed formulation patents are central to Paragraph IV and generic-entry analysis.
• The highest-value excipient opportunities are improved uniformity, reduced leakage, non-animal shells, longer stability, and lower-cost manufacturing.
• A successful generic could design around narrow excipient claims by changing the lipid vehicle, shell, capsule dimensions, or release profile.
• Mayne Pharma's ownership of the product creates potential opportunities for regional licensing, authorized generic supply, and formulation partnerships.
• Generic erosion risk is highest from a therapeutically equivalent softgel rather than from a tablet or cream alone.

FAQs About IMVEXXY Excipient and Patent Opportunities

Can IMVEXXY be reformulated without changing its FDA approval?

A material change to the excipient system, shell, fill, release profile, or stability profile may require a supplemental FDA filing. The regulatory pathway depends on the nature and extent of the change.

Which excipient is most important in an IMVEXXY-style product?

The lipid fill vehicle is usually the most important excipient because it affects estradiol solubility, content uniformity, leakage, release, and stability.

Is a generic IMVEXXY required to use the same excipients?

No. An ANDA applicant generally may use different inactive ingredients if the product meets applicable pharmaceutical equivalence, safety, quality, and bioequivalence requirements and does not infringe valid patent claims.

Can a non-gelatin IMVEXXY competitor obtain FDA approval?

Potentially. The alternative shell must satisfy safety, quality, performance, stability, and bioequivalence requirements. It may also need to avoid listed patent claims.

Does IMVEXXY have biosimilar competition?

No. IMVEXXY contains estradiol, a small-molecule active ingredient. Competition would proceed through generic drug pathways, not the biosimilar pathway.

Sources

1. U.S. Food and Drug Administration. (2018). IMVEXXY (estradiol vaginal inserts) prescribing information.
2. Mayne Pharma. (2022). Mayne Pharma completes acquisition of TherapeuticsMD women's health assets.
3. U.S. Patent and Trademark Office. (2018-2021). U.S. Patent Nos. 9,937,191 and 10,292,940 and related patent records.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.